Qiagen (NYSE:QGEN) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Qiagen (NYSE:QGEN - Get Free Report) released its earnings results on Wednesday. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.01, Zacks reports. Qiagen had a return on equity of 13.97% and a net margin of 4.23%. Qiagen updated its Q1 2025 guidance to 0.500- EPS and its FY 2025 guidance to 2.280- EPS.

Qiagen Stock Down 2.6 %

Shares of NYSE:QGEN traded down $1.11 during mid-day trading on Friday, reaching $41.34. 1,306,855 shares of the stock were exchanged, compared to its average volume of 1,330,707. The stock's 50 day simple moving average is $43.78 and its 200-day simple moving average is $43.29. Qiagen has a one year low of $40.15 and a one year high of $49.30. The company has a market cap of $9.17 billion, a P/E ratio of 115.09, a P/E/G ratio of 3.29 and a beta of 0.36. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on QGEN. HSBC lowered shares of Qiagen from a "buy" rating to a "hold" rating and set a $47.64 price objective on the stock. in a research note on Thursday, October 17th. Morgan Stanley reissued an "equal weight" rating and issued a $46.67 price target (down previously from $48.61) on shares of Qiagen in a report on Monday, January 6th. UBS Group lowered their price objective on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a research report on Friday. Jefferies Financial Group reiterated a "buy" rating and set a $52.50 target price (up from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Finally, Hsbc Global Res upgraded Qiagen to a "hold" rating in a report on Thursday, October 17th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $48.78.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.